Progress in the Study of the Therapeutic Effects of Roxarestat
DOI:
https://doi.org/10.53469/jcmp.2024.06(10).04Keywords:
Roxarestat, Hypoxia-inducible factor, Chronic kidney disease, AnemiaAbstract
Hypoxia-inducible factor has a wide range of roles in the human body and is involved in pathophysiological processes including erythropoietin production, iron uptake metabolism and energy metabolism. Roxarestat is a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase, which can stabilize the level of hypoxia-inducible factor to participate in systemic biological functions. Roxarestat is widely used in the treatment of renal anemia. With the deepening of research, it is found that roxarestat has therapeutic potential for renal fibrosis, cardiovascular disease, retinopathy, etc. This article summarizes the current status of roxarestat in the treatment of renal anemia, and its therapeutic effects on other therapies.
References
van Haalen Heleen, Sloand James, Moon Rebecca, et al. Drug treatment patterns and work productivity in chronic kidney disease patients with anemia in China: cross sectional analysis of real-world data[J]. KIDNEY RESEARCH AND CLINICAL PRACTICE, 2020, 39(3):318-333.
Working Group on Guidelines for Nephrogenic Anemia, Chinese Physicians Association Nephrologists Branch. Clinical practice guidelines for the diagnosis and treatment of renal anemia in China. Chinese Medical Journal, 2021, 101(20):1463-1502.
LIN Xiaozhen, ZHOU Jing. Research progress on the causes and related mechanisms of renal anemia[J]. Journal of Nanchang University (Medical Edition), 2022, 62(04):95-101.
Kidanewold A, Woldu B, Enawgaw B. Role of Erythropoiesis Stimulating Agents in the Treatment of Anemia: a Literature Review. Clin Lab. 2021;67(4). 10. 7754/Clin. Lab. 2020. 200817.
Coyne DW, Roger SD, Shin SK, et al. Roxadustat for CKD-related Anemia in Non-dialysis Patients. Kidney Int Rep. 2020;6(3):624-635.
Hou YP, Mao XY, Wang C, et al. Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial. J Formos Med Assoc. 2022; 121(2): 529-538.
LIU Mengjun, CHEN Shoukun, HAN Liuxin, et al. Observation on the efficacy of roxarestat in the treatment of EPO-resistant maintenance hemodialysis patients with HIV/AIDS[J]. Journal of Kunming Medical University, 2024, 45(08):139-144.
Wu M, Chen W, Miao M, et al. Anti-anemia drug FG4592 retards the AKI-to-CKD transition by improving vascular regeneration and antioxidative capability. Clin Sci (Lond). 2021;135(14):1707-1726.
Yang H, Wu Y, Cheng M, et al. Roxadustat (FG-4592) protects against ischaemia-induced acute kidney injury via improving CD73 and decreasing AIM2 inflammasome activation. Nephrol Dial Transplant. 2023;38(4):858-875.
HE Quan, QU Ning, LEI Zitong, et al. Effects of roxarestat on intestinal biobarrier function in CKD rats[J]. Western medicine, 2024, 36(02):166-174.
Huo Dongmei, FG-4592, Mechanism study on the protection of contrast-induced acute kidney injury [D]. Guangxi Medical University, 2021.
Schley G, Klanke B, Kalucka J, et al. Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis. Kidney Int. 2019; 96(2): 378-396.
Del Vecchio L, Locatelli F. Roxadustat in the treatment of anaemia in chronic kidney disease. Expert Opin Investig Drugs. 2018;27(1):125-133.
Sanghani NS, Haase VH. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience. Adv Chronic Kidney Dis. 2019;26(4):253 -266.
Gao Y, Jiang X, Yang D, et al. Roxadustat, a Hypoxia-Inducible Factor 1α Activator, Attenuates Both Long- and Short-Term Alcohol-Induced Alcoholic Liver Disease. Front Pharmacol. 2022;13:895710.
Li N, Cui W, Mu D, et al. Effects of roxadustat on thyroid hormone levels and blood lipid metabolism in patients undergoing hemodialysis: a retrospective study. Int J Med Sci. 2024;21(10):1806-1813.
ZHAO zhuo, WANG He. Progress of research on the mechanism of hypoxia-inducible factor 2α in cardiovascular system diseases[J/OL]. Chinese general medicine, 1-8.
Kido M, Du L, Sullivan CC, et al. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol. 2005; 46(11): 2116-2124.
Zhang X, Zhang Y, Wang P, et al. Adipocyte Hypoxia-Inducible Factor 2α Suppresses Atherosclerosis by Promoting Adipose Ceramide Catabolism. Cell Metab. 2019;30(5):937-951. e5.
Yu J, Wang S, Shi W, et al. Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS. JCI Insight. 2021;6(18):e133690.
Barratt J, Sulowicz W, Schömig M, et al. Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies. Adv Ther. 2021; 38(10):5345-5360.
Fishbane S, Pollock CA, El-Shahawy M, et al. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis. Results from the Randomized Phase 3 ROCKIES Study. J Am Soc Nephrol. 2022;33(4):850-866.
Hong Yi-Fen, Wang ZQ, Peng HW, et al. Efficacy of roxarestat versus erythropoietin in the treatment of hemodialysis-combined renal anemia in the elderly and the effect on cardiovascular indices[J]. Chinese Journal of Gerontology, 2023, 43(12):2903-2906.
Saygin C, Carraway HE. Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021;48:100791.
Mittelman M, Henry DH, Glaspy JA, et al. Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial. Am J Hematol. 2024;99(9):1778-1789.
Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31:107-25.
Wang H, Cheng Y, Mao C, Liu S, Xiao D, Huang J, et al. Emerging mechanisms and targeted therapy of ferroptosis in cancer. Mol Ther. 2021;29:2185 Mol Ther. 2021;29:2185-208.
Su X, Xie Y, Zhang J, et al. HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis [published correction appears in Cell Death Dis. 2023 Jan 17;14(1):31. Cell Death Dis. 2022; 13(10):861.
Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012; 367(26): 2515-2526.
Hoppe G, Bolok Y, McCollum L, Zhang J, Sears JE. Rank Order of Small Molecule Induced Hypoxiamimesis to Prevent Retinopathy of Prematurity. front Cell Dev Biol. 2020;8:488.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Zicheng Jin, Kai Qu, Ziqing Zhang, Renwei Zhao
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
